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STATEMENT OF TRANSLATIONAL RELEVANCE 
Quantitative profiling of protein abundance in tumors from a racially diverse breast cancer cohort by 
digital analysis of immunohistochemically stained tissue reveals gene regulators and gene regulatory 
networks that are differentially predictive of breast cancer survival based on race. These findings provide 
a deeper understanding of the association between predictive breast cancer biomarkers and their 
intrinsic downstream mechanisms and how such associations may differ by race.  Such observations 
offer new insights that will enable the identification of more accurate breast cancer biomarkers with 
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Background: Compared to their European American (EA) counterparts, African American (AA) women 
are more likely to die from breast cancer in the United States. This disparity is greatest in hormone 
receptor-positive subtypes. Here we uncover biological factors underlying this disparity by comparing 
functional expression and prognostic significance of master transcriptional regulators of luminal 
differentiation. 
Methods:  Data and biospecimens from 262 (AA) and 293 (EA) patients diagnosed with breast cancer 
from 2001-2010 at a major medical center, were analyzed by immunohistochemistry (IHC) for functional 
biomarkers of luminal differentiation including estrogen receptor (ESR1), and its pioneer factors FOXA1 
and GATA3. Integrated comparison of protein levels with network-level gene expression analysis 
uncovered predictive correlations with race and survival.  
Results: Univariate or multivariate hazard ratios (HRs) for overall survival, estimated from digital IHC 
scoring of nuclear antigen, show distinct differences in the magnitude and significance of these 
biomarkers to predict survival based on race: ESR1 (EA HR= 0.47, 95% CI: 0.31-0.72; AA HR= 0.77, CI: 
0.48-1.18); FOXA1 (EA HR= 0.38, CI: 0.23-0.63; AA HR = 0.53, CI: 0.31-0.88); and GATA3 (EA HR= 
0.36, CI: 0.23-0.56; AA HR= 0.57, CI: 0.56-1.4).  Additionally, we identify genes in the downstream 
regulons of these biomarkers highly correlated with race and survival. 
Conclusion: Even within clinically homogeneous tumor groups, regulatory networks that drive mammary 
luminal differentiation reveal race-specific differences in their association with clinical outcome. 
Understanding these biomarkers and their downstream regulons will elucidate the intrinsic mechanisms 
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The incidence of invasive breast cancer in the United States will approach 260,000 this year with over 
40,000 annual deaths.   Although overall breast cancer mortality has declined, the survival gap between 
African American and European American women continues to widen (1-9).  Women of African heritage 
suffer higher frequencies of triple-negative breast cancer (TNBC),  a more aggressive form of breast 
cancer characterized by the absence of the estrogen receptor (ER), the progesterone receptor (PR), and 
non-amplified expression of the human epidermal growth factor receptor 2 (HER2) (10-12).  Though 
recent studies have identified genetic components associated with African heritage that is linked to the 
higher frequency of TNBC (13), other studies have also shown significant race-based disparities in 
patients with hormone receptor-positive breast cancer (2,3,14).   These differences persist even after 
controlling for socioeconomic status (2,3,15-17), thus implicating roles for intrinsic biological factors.  
The transcriptional program driven by estrogen receptor plays a major role in mammary biology. 
Throughout the menstrual and reproductive cycles, its activity and levels regulate dynamic shifts in 
glandular proliferation and differentiation and play definitive roles during lactation and mammary gland 
involution (18,19). Once bound to ligand, estrogen receptor orchestrates major changes in chromatin 
structure that facilitate entry and assembly of large multi-component transcriptional complexes charged 
with executing cell-specific gene expression programs that influence tumor growth and initiation (18,19).  
This action provides the theoretical foundation for many endocrine-based therapeutic strategies (20,21).   
FOXA1 and GATA3 are sequence-specific DNA-binding transcription factors that function as chromatin 
pioneer factors essential for estrogen receptor function (22-26).  As pioneer transcription factors, they 
interact directly with histones to facilitate nucleosome displacement, chromatin remodeling, and the 
subsequent entry or binding of estrogen receptor (22,24,27).  Both factors play a significant role in 
sustaining the estrogen response because they are both induced and reciprocally activated by estrogen 
receptor (26,28,29).  FOXA1 and GATA3 play unique and overlapping roles in maintaining epithelial 
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differentiation by activating genes responsible for luminal features while repressing genes associated 
with basal or mesenchymal phenotypes (26,30-32). Unlike FOXA1, GATA3 is frequently altered (~10%) 
in breast cancer often with mutations limited to one allele suggesting a gain of function (22).  However, 
many known breast cancer-associated gene variants occur at genetic loci containing FOXA1 binding 
sites (33).  Interestingly, African American women show parity-associated reductions in FOXA1 
expression due to promoter methylation (34) while, in contrast, FOXA1 promoter methylation is reduced 
by BRCA1, whose transcription is controlled by ER (ESR1) (35).  These diverse interdependent modes 
of regulatory function and control exemplify how ESR1, FOXA1, and GATA3 act as master regulators to 
exert profound influence on breast cancer differentiation, prognosis and response to therapy. 
In this study, we explore the racial differences in the relationship between the protein expression of the 
ER, FOXA1 and GATA3 master regulators and overall breast cancer survival. Moreover, we identify 
intrinsic differences in the downstream transcriptional regulatory activity they govern to reveal new and 
novel gene classes that are predictive of race and three-year survival.   
 
Patients and Methods 
Study population, Tissue Microarray Construction, and Analysis 
Following IRB approval from East Carolina University and the National Institutes of Health intramural 
research program, de-identified formalin-fixed and paraffin-embedded tissue samples and de-identified 
clinical information abstracted from the medical records were requisitioned and initially procured for 733 
breast cancer patients who underwent surgery for Stage 0 to Stage IV breast cancer between 2001 and 
2010 at Pitt County Memorial Hospital (now Vidant Medical Center), Greenville, NC.  All patient samples 
and data obtained were de-identified and approved by the East Carolina University Institutional Review 
Board as a human subject exempt project, for which no informed consent is needed. The study was 
conducted in accordance with the Declaration of Helsinki. Race and/or ethnicity were self-reported at the 
initial visit and captured in the medical record.  Survival was recorded retrospectively from the medical 
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records and the cancer registry.  Median follow-up is 8.5 years.  588 patient blocks from this cohort were 
found suitable for use in the construction of a tissue microarray. Replicate tissue microarrays were 
constructed using 1 mm cores in accordance with previously described methods (36,37), with a complete 
representation of 555 patients.  Detailed methods for IHC, scoring and the assignment of clinical 
variables are provided in the supplemental data.   
 
Gene expression profiling 
Analysis of a portion of the breast cancer samples (Total N=126; EA N= 61; AA N= 65) was carried out 
by RNA-seq.  Following a review of H&E stained slides, areas for tumor with >80% nuclei were circled, 
and 2.5 x 2-3 mm tissue cores were extracted from the corresponding regions of FFPE tissue blocks.  
Cores were shipped to the Beijing Genomics Institute (BGI) (Beijing, China) where RNA was extracted 
and sequenced (60M paired-end reads per sample) as previously described (38,39). Detailed methods 
for sequencing and description of the analytical pipeline is provided in the data supplement.  
Statistical Analysis 
A linear model estimating outcomes for overall survival, 3-year survival, 5-year survival and race was 
applied to measure differences in the association of the digital score of nuclear proteins (OR, confidence 
interval and p-value) while controlling for clinical factors including age, stage, grade, subtype, and lymph 
node status (40). A comparison of IHC scoring was performed by the two-sided t-test and plotted as 
previously described (41). Multivariate Cox proportional-hazards model was used to test the independent 
and combined prognostic values of proteins of interest with/without the presence of selected clinical 
variables.  A Spearman rank correlation was performed to test the relationship between protein H-score 
and gene expression (RPKM) values (42). The significance of individual hazard ratios was estimated by 
Wald’s test.  Unsupervised hierarchical clustering of digital IHC protein data from all breast samples was 
performed using complete linkage and distance correlations with bootstrap resampling and estimated 
stability of clustering using the ‘pvclust’ R package (43).  Optimal cutoff points for H-score were 
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determined as previously described (44).  Prediction ability for race and 3-year survival by the regulon 
genes downstream of master regulators was determined univariately by area under the curve (AUC) 
receiver operator characteristics (ROC) (45). To define genes that optimized prediction (AUC), genes 
were added one by one, according to their ranking (univariate, high to low), to the logistic model in Monte 
Carlo simulations.  Protein interaction networks were generated with STRING using the minimum 
required interaction score of 0.15 (46).  Detailed statistical methods are provided in the supplemental 
data.  R/Bioconductor version 3.5.1 was used for the entire analysis. 
Results 
Racial Differences in Survival outcome of ER+ versus ER- breast cancer.   
The breast cancer cohort profiled in this study is racially diverse (53% European, N= 293; 47% African, 
N=262) (Figure 1A). Correlation between race, clinical, and pathologic characteristics are provided in 
Table 1.   As reported in prior studies, Luminal A subtype frequency is lower in African American 
compared to European American women, while the frequency of TNBC is higher in women of African 
heritage (Figure 1A, Table 1). This trend is consistent with those reported by other larger studies in the 
U.S.(10,47,48) and is representative of the subtype distribution in the parent population in the East 
Carolina cancer registry (Supplementary Figure 1).  Kaplan-Meier analysis of overall survival associated 
with estrogen receptor status confirm the know survival advantage for estrogen receptor positive (ER+) 
compared to estrogen receptor negative (ER-) breast cancer patients (Figure 1B).  However, this 
receptor positive survival advantage differs significantly by race, i.e. ER+  European American women  
show much more favorable survival than their African American counterparts (Figure 1C,D).    
Co-expression analysis of estrogen receptor and other biomarkers that distinguish luminal versus 
mesenchymal differentiation (FOXA1, GATA3, E-cadherin, HER2, versus EGFR) reveals significant 
biphasic correlations between ER expression and its pioneer factors (FOXA1 and GATA3) (Figure 1E).  
The biphasic nature of the distribution of ER, FOXA1 and, to a lesser extent GATA3, is consistent with 
the clustering by receptor status abstracted from the medical records, older age, menopausal status and 
intrinsic subtype (also see Table 2). Within the multivariate setting overall survival is independently 
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associated with age and subtype (Table 2).  As has been described for the ER+ classification, LumA 
subtype when compared to TNBC is associated with a favorable survival (Table 2, Supplement Figure 2). 
However, consistent with the differential racial association of ER status with overall survival, the relative 
hazard of LumA subtype decreases for European American women while it increases for of African 
American women (Supplemental Figure 2). Comparison of relative Luminal A breast cancer survival 
between African American and European American women shows a non-significant trend toward lower 
survival in women of African heritage with negligible difference in survival for TNBC (Supplemental 
Figure 3).  
 
The association between master regulators of luminal differentiation and overall survival in breast cancer 
patients differs by race 
To evaluate the independent predictive value of estrogen receptor, and the pioneer proteins FOXA1 and 
GATA3, IHC scores and overall survival outcomes were compared across the cohort before and after 
stratification by race (Figure 2). Optimum cutoffs for ESR1, FOXA1 and GATA3 histological scores were 
defined by exact distribution of maximally selected rank statistic. Using the population cutoff score for 
each antigen, Kaplan Meier analysis of the total cohort before and after stratification by race is shown in 
Figure 2A-C.  For all biomarkers, including ESR1, FOXA1 and GATA3, application of the optimized cutoff 
is predictive of favorable survival in the total cohort population. However, these predictive values show 
significantly less favorable or non-significant hazard ratios in African American compared to of European  
American women (Figure 2A-C).   Notably, this difference in survival exists despite the absence of any 
significant racial difference in the levels of either ESR1, FOXA1, GATA3, or the other biomarkers 
associated with luminal differentiation (CDH1, EGF, HER2) (Supplemental Figure 4).  Such observations 
strongly implicate influences downstream of ESR1, FOXA1, and GATA3 as possible contributors to the 
racial difference in survival outcome.  
To examine whether or not race-specific cutoff for these biomarkers might influence their predictive 
value, the optimal cutoff for ESR1, FOXA1, and GATA3 were again defined by determining the exact 
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distribution of the maximally selected rank statistic for these antigens separately for European  American 
and African American patients (Figure 2D).  For both ESR1 and FOXA1 the maximally selected cutoff for 
African American patients is higher than either those of European American or the total population 
(Figure 2D, top). In contrast, GATA3, one of the most highly mutated genes in breast cancer with higher 
frequencies in American  women (49), showed an optimal cutoff, in African American patients that is 
significantly lower than European American women or the total population (Figure 2D, bottom).    
 
A comparison of race-based biomarker cutoffs 
Comparative analysis of the predictive value of race-based cutoffs for ESR1, FOXA1 or GATA3 
expression, across the total breast cancer cohort, reveals that the cutoff for African American patients is 
considerably less predictive or non-significant in determining favorable overall survival (Figure 3A). In 
each instance, either the total population optimized cutoff, or the cutoff optimized in the European 
population has the highest predictive discrimination within the entire breast cancer cohort.  This 
relationship persists even when the race-optimized cutoffs are applied across races (e.g. EA-Cutoff (AA), 
Figure 3A). Although the influence of other non-biological factors that operate differently by race cannot 
be excluded (e.g. access to care, time of treatment and type of treatment); such findings suggest that 
these master regulators of luminal differentiation, may either be functionally less efficient or have 
reduced transcriptional activity in the downstream regulatory pathways in African American patients. 
To determine the relative contribution of the pioneer proteins FOXA1 and GATA3 as established 
modulators of estrogen receptor function in predicting overall survival, we compared how expression of 
FOXA1 or GATA3 stratified the relative hazard of low risk patients defined by high estrogen receptor 
expression.  Patients with high ESR1 expression, based on the population optimized cutoff (Figure 2A), 
were analyzed for overall survival using each of the optimized cutoff expression values derived from the 
total cohort, the European American, or the African American patients, respectively (Figure 3B, C).  
Within both the total patient cohort and European American patients, expression of either FOXA1 or 
GATA3 stratifies poor from favorable survival in patients with high estrogen receptor levels (Figure 3B, C; 
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left and middle panel).  In contrast, neither FOXA1 nor GATA3 expression provides significant prediction 
of survival in African American patients (Figure 3B, C; right panel).    
Univariate modelling demonstrates that FOXA1 measurements significantly outperform both ER and 
GATA3 as predictors of favorable overall breast cancer survival (Figure 3D, top left). This relationship 
persists even after adjusting for age, race and stage in multivariate analysis (Figure 3D, top right).  
Notably, multivariate models adjusting for expression of the other two master regulators, reveal that only 
FOXA1 is an independent predictor of overall breast cancer survival controlling for either age, race, 
stage, or the expression of either GATA3 or ESR1 (Fig. 3D, bottom right).   
The racial disparity in the association of luminal master regulator expression with breast cancer survival 
implicates altered activity of downstream transcriptional networks as a source of differences in tumor 
biology. Recent advances in systems level understanding of transcriptional regulation have developed 
powerful approaches to define and measure the total transcriptional function and/or “activity” of specific 
transcription factors by collectively assessing expression of the network of their downstream regulatory 
targets or “regulons” (50). Computational recognition and construction of these gene networks are 
available from the collective analysis of publicly available gene expression data sets (50,51). Using the 
Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNe) (52) and publicly available 
human breast cancer gene expression data sets provided through TCGA, Walsh et al. defined the 
regulons controlled by ESR1, FOXA1, and GATA3 (see additional data, (50)). The RNA-seq gene 
expression data for twenty-two percent (22%) of this cohort (deceased patients, N=126) was used to 
uncover genes, controlled by ESR1, FOXA1 or GATA3, that either distinguish race or predict 3-year 
survival (Figure 4A, B).  Using logistic probability distribution modeling through Monte Carlo simulations, 
each gene in the regulons of ESR1 (985 genes), FOXA1 (1478 genes), and GATA3 (871 genes) (see 
supplementary material) were combinatorially profiled for their ability to contribute to the prediction of 
either race or 3-year survival. Optimum predictive value was assessed through area under the curve 
(AUC) determinations based on receiver operator curve (ROC) analysis (Figure 4A, B). This method 
identified eleven (11) genes in the ESR1 regulon that contributed to distinguishing race, and eight (8) 
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genes that predicted 3-year survival. Sixteen (16) genes were identified in the FOXA1 regulon that 
distinguished race and eleven (11) genes that predicted 3-year survival.  Finally, in the GATA3 regulon, 
twelve (12) genes were identified as discriminators of race while twelve (12) genes were found to predict 
3-year survival (Figure 4A, B; supplemental Tables 1). Notably, many of these genes are significantly 
associated with relapse free survival (RFS) in independent gene expression data sets (Figure 4C, D; 
supplemental Table 2). Based on an analysis of known/predicted, direct or functional gene-gene 
interactions defined within the String database, the linkages of ESR1, FOXA1, and GATA3 the regulon 
gene groups (race and 3-year survival, respectively) could be assembled into two distinct networks 
anchored by the ESR1, FOXA1 and GATA3 regulatory triad (Fig 4E, F).  The functional cellular 
processes significantly enriched by inclusion of first-degree interactions of these networks includes 
multiple metabolic processes involving amino acid, vitamin and one carbon metabolism (race predictive 
network; Figure 5A; supplemental table 3); and multiple pathways linked to tissue and cellular 
differentiation, Wnt signaling, and chromatin modifications (3-yr Survival predictive network; Figure 5B; 
supplemental table 3).  The gene expression correlation matrix (spearman) of the racial and survival 
predictors shows strong similarities (discordance in only two genes) in clustering of the master regulatory 
triad expression data in both the ECU patient cohort and the TCGA data set (Figure 5C). Finally, in 
validation studies, the ROC analysis of ECU racial predictor genes shows strong agreement with the 
TCGA data (Figure 5D and 5E).   
 
Discussion 
In this report, we provide an advanced analytical characterization of a retrospective cohort of racially 
diverse breast cancer patients collected from a single catchment area in rural East North Carolina. Using 
this unique cohort, we show that functional predictors of favorable outcome, defined by expression of 
transcriptional master regulators of mammary luminal differentiation, reveal significant racial differences 
in their predictive association with favorable outcome. This finding is consistent with other reports 
indicating that African American women experience significantly less favorable outcome even when 
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stratified, by biomarker profiling, into forms of breast cancer that typically show favorable outcome in 
European American  women (3,10,15,16). Limitations of this study includes a lack of precise 
determination of the socio-economic status of the patients in this cohort, thus the contribution of racial 
differences in access to care, quality and adherence to treatment cannot be ruled out (53).  Nonetheless, 
an analysis of the median incomes of the counties in which each patient was diagnosed reveals 
significant differences for outcome in European American women (HR =0.6, p= 0.012) compared to a 
smaller, non-significant trend (HR=0.73, p=0.13) in African American women (Supplemental Fig 5). In 
addition, ESR1-positive tumors are less common in African American women, and therefore the sample 
size for patients with higher expression of FOXA1 and GATA3 is lower (26% and 16% respectively).  
Thus, given the samples size, the cutoff determinations may not be totally stable. Other, evidence 
supporting race-based differences in the intrinsic biology of luminal tumors is provided by two recent 
reports by Holowatyi, et al. (54) and Troester et al. (55).  These studies  showed that African American 
women are more likely to have higher risk assessments in the 21 gene recurrence score (RS) breast 
cancer assay, and PAM 50 risk of recurrence (ROR) scoring, even after adjusting for age, clinical stage, 
tumor grade, and histology (54,55).   
An overarching hypothesis to explain the racial differences in the association of these functional 
biomarkers with survival outcome, despite similar levels of favorable biomarker expression, is disparate 
function of the downstream networks governed by these transcriptional master regulators. This could 
occur through a variety of transcriptionally-linked mechanisms including: 1) polymorphisms in promoter 
or enhancer transcription factor binding sites; and/or 2) differences in the coding sequence of the 
individual constituents of multicomponent transcriptional complexes that disrupt assembly of the complex 
without influencing the stability of the individual components.  Several breast cancer-associated risk loci 
contain FOXA1 binding sites (33,56) and current exome sequencing studies have identified multiple 
variations in the coding sequence of genes in racially diverse populations (57). Many of these variants do 
not predict protein instability or are of unknown prevalence and consequence in populations of defined 
genetic ancestry (57).  It is conceivable that such “variants of unknown significance” (VUS) could have 
substantial roles in determining the downstream transcriptional activity in pathways that play important 
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roles in mammary growth, differentiation and breast cancer outcome.  The level, activity and mutational 
spectrum of the predictive regulon genes, described in this study, provide a cogent starting point for their 
future investigation as predictive breast cancer biomarkers and functional targets for therapy.  Given the 
role of ESR1, FOXA1, and GATA3 in enhancer function, the role of long-range chromatin interactions, 
chromosomal domains, and chromatin looping in breast cancer incidence, progression, diagnosis and 
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HR,  95% CI p-value 
      





     
Premenopause 
(AGE<50) 
150 66 (12%) 84 (15%) 1  
Postmenopause 
(AGE>50) 
405 227 (41%) 178 (32%) 1.1281 (1.0275 - 1.2384) 
 
0.0115 
Grade      
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Percentages (%) provided indicate percent of total sample (N=555) for each variable. Hazard ratios are 
presented with European American patients (presumed from self-reporting) as the referent. Continuous 
variable = age; unit = years. All other variables are categorical. NA= not available; LN = lymph node. 
Hazard ratios (HRs) for clinical variables are calculated based on racial differentiation (i.e. EA versus AA) 






Table 2 Univariate and multivariate correlation of patient clinico-pathological 
characteristics with overall survival by Cox regression analysis 
Low 147 85 (15%) 62 (11%) 1  
Moderate 258 135 (25%) 123 (22%) 1.0565 (0.9547 - 1.1692) 0.2869 
High 88 40 (7%) 48 (9%) 1.1317 (0.9916 1.2916) 0.0665 
NA's 62 33 (6%) 29 (5%)   
Stage      
0 56 31 (6%) 25 (5%) 1  
1 184 116 (21%) 68 (12%) 0.9260 (0.7985 - 1.0739) 0.3085 
2 185 91 (16%) 94 (17%) 1.0636 (0.9173 - 1.2333) 0.4134 
3 74 28 (5%) 46 (8%) 1.1915 (1.0033 - 1.4149) 0.0458 
4 38 19 (3%) 19 (3%) 1.055 (0.8604 - 1.2938) 0.6061 
NA 18 8 (2%) 10 (2%)   
Node      
LN- 308 178 (32%) 130 (23%) 1  
LN+ 201 92 (17%) 109 (20%) 1.1277 (1.0322 - 1.2320) 0.0078 
NA 46 23 (4%) 23 (4%)   
 Univariate Analysis Multivariate Analysis 
 HR 95% CI p-value HR 95% CI p-value 
Age 1.013 (1.001-1.03) 0.03 1.02 (1.01-1.04) 0.002 
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HR: hazard ratio, CI: confidence interval is given for overall survival. Multivariate analysis controlled for age, race, menopause 
status and subtype respectively. Criteria for subtype assignments are provided in the supplementary methods section. Race 






















Race       
European 1      
African 1.06 (0.77-1.4) 0.73 1.17 (0.88-1.57) 0.29 
Menopause Status       
Post-menopause 1      
Pre-menopause 0.8 (0.56-1.2) 0.24 1.18 (0.72-1.96) 0.51 
Subtype       
Lum A 1      
Lum B 1.775 (1.174-2.684) 0.00653 1.743 (1.1518-2.636) 0.0009 
HER2+ 2.06 (1.15-3.691) 0.01518 2.145 (1.1955-3.847) 0.011 
TNBC 3.253 (2.264-4.676) 1.81E-10 3.552 (2.4596-5.128) 1.37E-11 
Research. 
on April 23, 2020. © 2020 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 




Fig 1. Racial differences in the association of estrogen receptor expression and survival in a 
diverse breast cancer cohort.  (A) Subtype distribution of European American (EA, N=292) and 
African American (AA, N=260) breast cancer patients. (B) Kaplan-Meier analysis of overall 
survival comparing estrogen receptor-positive (ER+) to estrogen receptor-negative (ER-) breast 
cancer patients. (C) Survival profiling of ER+ versus ER- breast cancers in European American 
patients. (D) Survival profiling of ER+ versus ER- African American breast cancer patients. (E) 
Hierarchical clustering of quantitative IHC expression (H-Score) of EGFR, E-cadherin (Ecad), 
human EGF receptor 2 (HER2), ER, GATA3 and FOXA1 with data distribution (right, yellow) 
and histogram (right, red). The scale bar represents the color distribution of a range of protein 
values. (underneath) Patient demographics and tumor characteristics, BMI, body mass index; 
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone 
receptor. EA, European American based on self-reporting; AA, African American based on self-
reporting. Color coding is indicated.   
   
Fig 2. Racial differences in the association of expression of master regulators of luminal 
differentiation with survival. Kaplan-Meier analysis of the association of ER expression (A), 
FOXA1 expression (B) confirms GATA3 expression (C) with survival in the total population (left), 
European American patients (center) and African American patients (right). (D) Determination of 
maximally selected rank statistic to define optimal H-score cutoff (black dashed line) for ESR1, 
FOXA1 and GATA3, analyzed for the total and race-stratified cohort EA, European American 
based on self-reporting; AA, African American based on self-reporting. Blue points represent 
protein expression values below optimum cutoff and red points represent protein values above 
the optimum cutoff.  
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Fig 3.  ER, FOXA1 and GATA3 have different predictive values for overall survival based on 
race. (A) Forest plot of hazard ratios (HR) of overall breast cancer survival using median and 
population optimized cutoff H-scores (ALL, EA, and AA) for ESR1, FOXA1 and GATA3 
expression. (B) Association between FOXA1 expression and survival in low risk, high ER 
expressing breast cancer patient, comparing the total population (left) with European  American 
patients, center; and African American patients, left. (C) Association between GATA3 
expression and survival in low risk, high ER expressing breast cancer patients, comparing the 
total population (left) with European American, (center); and African American patients (left). (D) 
Univariate and multivariate logistic regression models of overall breast cancer survival based on 
FOXA1, ESR1, and GATA3 expression adjusted for age, race, and stage. 95% confidence 
intervals are shown in parentheses.  CI=confidence interval. EA, European American based on 
self-reporting; AA, African America based on self-reporting. 
Fig 4. Receiver-operator characteristics (ROC) analysis with a set of optimized genes from 
ESR1, FOXA1, and GATA3 regulons that, combined, have the highest prediction (AUC) of race 
(A) or 3-year survival (B) determined by logistic regression.  (C,D) Volcano plots profiling the 
association of regulon genes that predict race (C) and 3-year survival (D) with relapse-free 
survival (RFS) in publicly available breast cancer gene expression data sets (see supplemental 
data).  Y-axis= -log P value, X-axis= coefficient of log scale hazard. CI, confidence interval. EA, 
European American based on self-reporting; AA, African American based on self-reporting. 
Green = genes enriched in EA; Red = gene enriched in AA.  E, F) Regulons genes and gene 
networks downstream of master regulators of luminal differentiation (ESR1, FOXA1 and 
GATA3) that optimally predict race and 3-year survival.  Lines indicate direct or regulatory 
interactions. The thickness of the lines indicates the relative strength of the interactions. 
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Figure 5. Functional cellular processes that are significantly enriched in first-degree interaction 
networks assembled from gene predictors of race (A) and 3-yr survival (B). Correlation matrix of 
racial and 3-yr survival gene predictors from the ECU (left) and TCGA (right) (C).  Concordant 
gene clusters and clustered genes are shown in red and blue. The most highly correlated genes 
shown in bold.  Discordant genes are shown in black.  ROC curve validation of ECU cohort 
derived racial predictors using the TCGA expression data set (D) show that many the predictive 
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